Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Februar 2023 08:30 ET | Quelle: Lantheus Holdings, Inc.

Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

BEDFORD, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...
06. Februar 2023 16:03 ET | Quelle: Lantheus Holdings, Inc.

Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease

BEDFORD, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...
04. Januar 2023 08:30 ET | Quelle: Lantheus Holdings, Inc.

Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference

NORTH BILLERICA, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
20. Dezember 2022 08:30 ET | Quelle: Lantheus Holdings, Inc.

Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma

NORTH BILLERICA, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
12. Dezember 2022 08:00 ET | Quelle: Lantheus Holdings, Inc.

Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform

NORTH BILLERICA, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
06. Dezember 2022 07:45 ET | Quelle: Lantheus Holdings, Inc.

Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027

NORTH BILLERICA, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced the pricing of $500 million in aggregate principal...
05. Dezember 2022 07:00 ET | Quelle: Lantheus Holdings, Inc.

Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027

NORTH BILLERICA, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced that it intends to offer, subject to market conditions...
29. November 2022 08:00 ET | Quelle: Lantheus Holdings, Inc.

Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial

NORTH BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
28. November 2022 08:00 ET | Quelle: Lantheus Holdings, Inc.

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
14. November 2022 07:00 ET | Quelle: Lantheus Holdings, Inc.

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticalsExpands Lantheus’ portfolio...

Vorherige Seite

Nächste Seite